Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 15, 2022 at 09:58 pm
Share
Daewon Pharmaceutical Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 188.27 million compared to KRW 25.78 million a year ago. Net income was KRW 7,401.82 million compared to KRW 3,048.42 million a year ago. Basic earnings per share from continuing operations was KRW 349 compared to KRW 144 a year ago. Basic earnings per share was KRW 349 compared to KRW 144 a year ago.
For the six months, sales was KRW 222.42 million compared to KRW 29.33 million a year ago. Net income was KRW 17,907.07 million compared to net loss of KRW 5,032.2 million a year ago. Basic earnings per share from continuing operations was KRW 844 compared to basic loss per share from continuing operations of KRW 237 a year ago. Basic earnings per share was KRW 844 compared to basic loss per share of KRW 273 a year ago.
Daewon Pharmaceutical Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceutical products. The Companyâs products include antipyretics, analgesics, anti-inflammatory drugs, respiratory drugs, gastrointestinal drugs, antimicrobial drugs, cardiovascular drugs, metabolic drugs, psychoneurotic drugs, neuromuscular drugs, endocrine drugs and others. The Company also produces multivitamins and health foods. The Company distributes its products within domestic market and overseas markets, including Vietnam, Myanmar, Southeast Asia, the Middle East and others.